Ascione
Alessandro Ascione, Roma IT
Patent application number | Description | Published |
---|---|---|
20120282257 | SINGLE-CHAIN VARIABLE FRAGMENT (SCFV) ABLE TO RECOGNIZE AND BIND CD99 HUMAN PROTEIN - The present invention relates to a single-chain variable fragment (scFv) able to recognize an epitope of the extracellular domain of CD99 human protein. | 11-08-2012 |
Alessandro Ascione, Rome IT
Patent application number | Description | Published |
---|---|---|
20130203964 | ANTIBODY DERIVATIVES - An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1. | 08-08-2013 |
Ester Ascione, Santa Maria Capua Vetere IT
Patent application number | Description | Published |
---|---|---|
20120296071 | TRANSFERRIN FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF AUTOIMMUNE DISEASES - The present invention describes pharmaceutical compositions containing APOTf for use in preventing (or delaying the onset) and treating autoimmune diseases. Based on the experimental data obtained, the molecule has the surprising capacity to favourably modify the immune response profile both in vitro and in vivo. | 11-22-2012 |
George Ascione, Cream Ridge, NJ US
Patent application number | Description | Published |
---|---|---|
20120275557 | Production of Radionuclide Molybdenum 99 in a Distributed and In Situ Fashion - A method and apparatus for producing Mo-99 from Mo-100 for the use of the produced Mo-99 in a Tc-99m generator without the use of uranium is presented. Both the method and apparatus employ high energy gamma rays for the transformation of Mo-100 to Mo-99. The high energy gamma rays are produced by exposing a metal target to a moderated neutron output of between 6 MeV and 14 MeV. The resulting Mo-99 spontaneously decays into Tc-99m and can therefore be used in a Tc-99m generator. | 11-01-2012 |
Giovanni Ascione, Rome IT
Patent application number | Description | Published |
---|---|---|
20130276857 | Electric and Mechanical Interconnection System of Photoelectrochemical Cells Modules - The present invention regards a module ( | 10-24-2013 |
Riccardo Ascione, Roma IT
Patent application number | Description | Published |
---|---|---|
20150284549 | TREAD COMPOUND PRODUCTION METHOD - A rubber compound production method including a first mixing step wherein at least one cross-linkable unsaturated-chain polymer base, silica, and a silane bonding agent in the alkoxymercaptoalkyl-silane class are mixed together; and a following mixing step wherein a curing system having at least sulphur and accelerants is added and mixed to the compound being produced. 0.2 to 5 phr of an accelerant, and 0.5 to 6 phr of a zinc salt of a fatty acid with a carbon atom number of C8 to C24 are added at the first mixing step. The accelerant is from the group of benzothiazyl-cyclohexyl-sulphenamide (CBS), benzothiazole disulphide (MBTS), N-tert-butyl-2-benzothiazylsulphenamide (TBBS), 2-mercaptobenzothiazole (MBT), zinc salts of 2-mercaptobenzothiazole (ZMBT), benzothiazyl-2-dicyclohexyl-sulphenamide (DCBS), diphenylguanidine (DPG), triphenylguanidine (TPG), diorthotolyl guanidine (DOTG), o-tolylbiguanidine (OTBG), ethylene thiourea (ETU) and their mixtures. | 10-08-2015 |
Richard Ascione, Jersey City, NJ US
Patent application number | Description | Published |
---|---|---|
20130064841 | IMMUNOGENIC COMPOSITIONS AGAINST HUMAN PROGASTRIN PEPTIDES - Immunogens against human extended-progastrin species comprise (A) a mimetic peptide comprised of (i) the amino acid sequence of a progastrin or a N- and/or C-terminal processed species of a progastrin joined to (ii) a 7 amino-acid spacer coupled to (B) an immunogenic carrier. Illustrative of the mimetic peptide/spacer combination are a 21 amino-acid peptide (SEQ ID NO.: 1) and other, related polypeptides (SEQ ID NOs.: 2-5). Pharmaceutical compositions containing such an immunogen display improved immunological properties, including the induction of effective antibody levels shortly after the administration of an initial course of immunogen. Levels of antibody thus elicited stay elevated for several months and readily elevate to higher levels upon subsequent boosting by a single injection of immunogen. | 03-14-2013 |